Amgen kept at neutral by Merrill

Merrill Lynch analyst Eric Ende maintained Amgen, Inc. at its neutral rating. The signed an exclusive five-year supply agreement with Fresenius that pre-emptively protects Amgen's market share in case CERA reaches the U.S. market in early 2007, according to the analyst. Terms of the contract were not disclosed, but it is believed to include incentive discounts and rebates. Amgen could sign similar deals with other dialysis companies, such as DaVita. Shares of the Thousand Oaks, Calif.-based biotechnology company were up 67 cents, or 0.93%, at $73.05. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.